Posted by Michael Wonder on 08 Oct 2021
ChemoCentryx announces FDA approval of Tavneos (avacopan) in ANCA associated vasculitis
8 October 2021 - First FDA approved orally administered inhibitor of the complement 5a receptor.
ChemoCentryx today announced that the U.S. FDA has approved Tavneos (avacopan), an orally administered selective complement 5a receptor inhibitor, as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis, specifically granulomatosis with polyangiitis and microscopic polyangiitis (the two main forms of ANCA vasculitis), in combination with standard therapy.
